Boyle D A, Goldspiel B R
Inova Fairfax Cancer Center, Falls Church, VA, USA.
Clin J Oncol Nurs. 1998 Oct;2(4):141-5.
The purpose of this article is to review information relative to the administration, stability, and compatibility of paclitaxel (Taxol, Mead Johnson Oncology Products, Princeton, NJ). The unique formulation used to solubilize paclitaxel has led to an increased awareness of plasticizer-leaching issues, paclitaxel stability in solution, and paclitaxel compatibility with other medications. Particularly with longer paclitaxel infusion schedules (greater than 48 hours), both drug stability in solution and pump apparatus congruence require careful consideration to minimize plasticizer-leaching problems and to ensure optimum drug delivery. Despite knowledge of the physical compatibility of paclitaxel with numerous drugs, a paucity of research has documented the specifics of paclitaxel's chemical compatibility with other medications.
本文旨在综述与紫杉醇（泰素，美赞臣肿瘤产品公司，新泽西州普林斯顿）的给药、稳定性及配伍性相关的信息。用于溶解紫杉醇的独特制剂引发了人们对增塑剂浸出问题、紫杉醇在溶液中的稳定性以及紫杉醇与其他药物配伍性的更多关注。特别是对于较长的紫杉醇输注方案（超过48小时），溶液中的药物稳定性和输液泵装置的适配性都需要仔细考虑，以尽量减少增塑剂浸出问题并确保最佳的药物递送。尽管已了解紫杉醇与多种药物的物理配伍性，但关于紫杉醇与其他药物化学配伍性细节的研究却很少。
